OXP005

DRUG2 trials

Sponsors

Oxford Pharmascience Ltd

Conditions

Gastroduodenal ErosionsPharmacokinetics

Phase 1

Phase I Study PK Study With OXP005 and Naprosyn

CompletedNCT02351024

Oxford Pharmascience LtdPharmacokinetics

Start: 2015-02-28End: 2015-03-31Updated: 2015-04-01

Pilot Study of OXP005 to Assess Gastroduodenal Irritation

CompletedNCT02408978

Oxford Pharmascience LtdGastroduodenal Erosions

Start: 2015-05-31End: 2015-06-30Updated: 2015-06-18